ArticleInternational journal of nanomedicine2026
Intranasal Delivery of Curcumin-Loaded Pure Drug Self-Assembled Lipid-Based Nanoparticles for Targeted Therapy of Depression.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Current antidepressants are limited by insufficient efficacy of conventional monoaminergic drugs and poor brain penetration across the blood-brain barrier. This study designed pure curcumin loaded lipid nanoparticle (CNP) with optimized brain-targeting delivery for depression therapy. Methods: Cur molecules first self-assembled into carrier-free drug nanoparticles. Subsequently, CNP were then prepared via thin-film dispersion and fully characterized in terms of particle size, PDI, DSC, XRD, TEM. The antidepressant effect of CNP was systematically investigated via in vitro and in vivo assays, including cellular uptake, LPS-induced stress model in BV2 cells, and in vivo CUMS depression model. Results: CNP displayed uniform spherical morphology with an average size of 115.8 ± 18.3 nm, PDI of 0.216 ± 0.015 and zeta potential of -27.1 mV, along with high encapsulation efficiency (86.11 ± 4.28%), drug loading (6.62 ± 0.45%) and sustained release behavior. The cellular uptake efficiency of the CNP group reached 41.47 ± 1.45%, which was more than double that of the Cur group (17.21 ± 0.54%). In vitro studies showed that CNP not only rescued the viability of cells damaged by corticosterone and hydrogen peroxide but also exerted significantly enhanced anti-inflammatory and antioxidant effects in lipopolysaccharide induced cellular stress models. In vivo studies indicated that CNP alleviated depressive-like behaviors more effectively. Conclusion: CNP exhibits significantly enhanced antidepressant efficacy, thus providing a promising approach for developing brain-targeted therapeutics for MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.